{"analyses":[{"ciLowerLimit":"0.78","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.09","groupDescription":"Stratified by: stage and/or surgical status (Stage III vs. Stage IV), ECOG performance status (0 vs. 1 or 2), tumor PD-L1 status (IC0 vs. IC1/2/3), and treatment strategy (adjuvant vs. neoadjuvant).","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.3432","paramType":"Hazard Ratio (HR)","paramValue":"0.92","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"45.31","upperLimit":"49.74","value":"46.59"},{"comment":"The upper limit of 95% CI was not estimable by Brookmeyer and Crowley method due to insufficient observed events.","groupId":"OG001","lowerLimit":"46.26","upperLimit":"NA","value":"50.53"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"650"},{"groupId":"OG001","value":"651"}],"units":"Participants"}],"description":"Overall Survival (OS) is defined as the time from randomization to death from any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab placebo IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab placebo for a total of 22 cycles of atezolizumab placebo and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and placebo for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and placebo for additional 16 cycles.","id":"OG000","title":"Placebo With Paclitaxel, Carboplatin and Bevacizumab"},{"description":"Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab for a total of 22 cycles of atezolizumab and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and atezolizumab for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and atezolizumab for additional 16 cycles.","id":"OG001","title":"Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab"}],"paramType":"MEDIAN","populationDescription":"Intent-to-Treat (ITT) population is defined as all randomized patients, whether or not the assigned study treatment was received.","reportingStatus":"POSTED","timeFrame":"From randomization up to death from any cause (up to approximately 59 months)","title":"Overall Survival - ITT Population","type":"PRIMARY","unitOfMeasure":"Months"}